Skip to main content

Table 3 Clinicopathological characteristics of HER2 amplified and HER2 non-amplified cases

From: Clinical and molecular characterization of HER2amplified-pancreatic cancer

Clinicopathological characteristics

Total cohort, n = 469

HER2 amplification

P-value

  

Amplified, n = 10

Non-amplified, n = 459

 

Sex, n (%)

    

 Male

241 (51)

6 (60)

220 (51)

0.7520b

 Female 

228 (49)

4 (30)

210 (49)

Age, years

    

 Mean

66

64

66

0.5467c

 Median

68

69.5

67.5

 Range

28 to 88

47 to 73

28 to 87

AJCC stage, n (%)

    

 1a

17 (3.6)

1 (10)

16 (3.5)

0.4495d

 1b

25 (5.3)

1 (10)

24 (5.2)

 2a

132 (28.1)

3 (30)

129 (28)

 2b

279 (59.5)

4 (40)

275 (60)

 4

16 (3.4)

1 (10)

15 (3)

T stage, n

    

 T1

32

1

31

 

 T2

64

2

62

 

 T3

372

7

365

 

 T4

1

0

1

 

N stage, n

    

 N0

180

6

174

 

 N1

289

4

185

 

AJCC grade, n

    

 1 (well differentiated)

36

0

36

0.1259d

 2 (moderately differentiated)

305

10

295

 3 (poorly differentiated)

125

0

125

 4 (undifferentiated)

3

0

3

Tumour size, mm

    

 <=20

105

3

102

0.4695b

 >20

364

7

357

Vascular invasion, n

    

 Present

222

2

220

0.1106b

 Absent

247

8

239

Perineural invasion, n

    

 Present

339

8

331

0.7336b

 Absent

130

2

128

Tumour location, n

    

 Head

381

9

372

0.6961b

 Others

88

1

87

 Margins

    

 Clear

301

7

294

1.0000b

 Involved

168

3

165

Outcome

    

 Follow-up, months 

0.03 to 240

5.0 to 43.6

0.03 to 240

1.0000b

 Median follow-up, months 

16

23

16

 Death: PDAC

369

8

361

 Death: other

32

2

30

 Death: unknown

16

0

16

 Alive

49

0

49

 Lost to follow-up

3

0

3

Cancer-specific survival, mean ± SD

    

 Length, months

20 ± 19.43

28 ± 19.65

20 ± 19.55

0. 2502c

Recurrence

    

 Present

261

8

253

 

 Absent

78

1

77

 

 Unknown

130

1

129

 

Pattern of recurrence, n (% of total n)

    

 Lung without liver metastasis

22 (8.4% of 261)

4 (50% of 8)

18 (7.1% of 253)

0.0022b

 Any recurrence without liver metastasis

127 (49% of 261)

8 (100% of 8)

119 (47% of 253)

0.0028b

Adjuvant therapy, n

    

 Yes

175

3

172

 

 No

289

7

282

 

 Unknown

5

0

5

 
  1. AJCC, American Joint Committee on Cancer; PDAC, pancreatic ductal adenocarcinoma.
  2. aAJCC Cancer Staging Manual, seventh edition.
  3. bFisher’s exact test.
  4. cUnpaired t-test.
  5. dχ2 test.